These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22204097)

  • 1. Monoclonal antibody use in inflammatory bowel disease.
    Hayes CE; Cerezo CS
    Med Health R I; 2011 Nov; 94(11):337-40. PubMed ID: 22204097
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological therapy of inflammatory bowel disease].
    Lazebnik LB; Parfenov AI; Kniazev OV; Konopliannikov AG; Sagynbaeva VE; Iakovleva MV; Astrelina TA; Ruchkina IN; Shcherbakov PL; Trubitsyna IE; Tsaregorodtseva TM; Gudkova RB; Rogozina VA; Chikunova BZ; Khomeriki SG; Mikhaĭlova ZF
    Eksp Klin Gastroenterol; 2011; (2):7-14. PubMed ID: 21560638
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppresive therapy for inflammatory bowel disease.
    Casis Herce B
    Rev Esp Enferm Dig; 2003 Jul; 95(7):456-8, 453-5. PubMed ID: 12952507
    [No Abstract]   [Full Text] [Related]  

  • 7. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolving knowledge and therapy of inflammatory bowel disease.
    Korzenik JR; Podolsky DK
    Nat Rev Drug Discov; 2006 Mar; 5(3):197-209. PubMed ID: 16518373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 10. [IL-17/IL-23: a new therapeutic target in inflammatory bowel diseases].
    Malamut G
    Gastroenterol Clin Biol; 2008 Mar; 32(3):354-6. PubMed ID: 18374530
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal antibodies, immunogenicity, and associated infusion reactions.
    Cheifetz A; Mayer L
    Mt Sinai J Med; 2005 Jul; 72(4):250-6. PubMed ID: 16021319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunobiology of chronic inflammatory bowel diseases].
    Siegmund B; Zeitz M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2657-60. PubMed ID: 17109275
    [No Abstract]   [Full Text] [Related]  

  • 14. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604.
    Caspersen S; Mortensen C; Riis L; Jess T; Bendtsen F
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1257. PubMed ID: 19778634
    [No Abstract]   [Full Text] [Related]  

  • 16. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of infliximab in inflammatory bowel disease needs to be debated.
    de Vries HS; Van Oijen MG; de Jong DJ
    Clin Gastroenterol Hepatol; 2009 May; 7(5):603-4. PubMed ID: 19166980
    [No Abstract]   [Full Text] [Related]  

  • 18. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 19. Methotrexate in inflammatory bowel disease.
    Feagan BG; Alfadhli A
    Gastroenterol Clin North Am; 2004 Jun; 33(2):407-20, xi. PubMed ID: 15177546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
    Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
    Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.